Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

OSE Immunotherapeutics (OSE) EUR0.2

Sell:€3.58 Buy:€3.63 Change: €0.03 (0.83%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Change: €0.03 (0.83%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Change: €0.03 (0.83%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body’s immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient’s specific cytotoxic T response against their cancer. The Company’s main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.

Contact details

22, boulevard Benoni Goullin
+33 (2) 28291010

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€53.88 million
Shares in issue:
14.93 million
Euronext Paris

Key personnel

  • Dominique Costantini
    Chairman of the Board
  • Alexis Peyroles
    Chief Executive Officer
  • Bernard Vanhove
    Deputy Chief Executive Officer
  • Maryvonne Hiance
    Vice Chairman of the Board, Chief Strategy Officer
  • Anne-Laure Autret-Cornet
    Chief Financial and Administrative Officer
  • Nicolas Poirier
    Scientific Director
  • Jean-Pascal Conduzorgues
    Director of Production
  • Frederique Corallo
    Medical Director Immunotherapies and Autoimmune Diseases
  • Julien Perrier
    Chief Commercial Officer
  • Emilienne Soma
    Director of Pharmaceutical Programs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.